Contraindicated (1)bortezomib will improve the degree or outcome of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or moderate CYP2C19 inhibitors might maximize mavacamten systemic exposure, resulting in heart failure as a result of systolic dysfunction. Drug Formulary data is meant for use by healthcare industry experts. It's not https://manleyp009iuf3.blogspothub.com/profile